TREM1 and septic shock: For example, levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), which are elevated in patients with sepsis and have been associated with poor outcomes [33], were used in a phase 2 trial of nangibotide, a TREM-1 inhibitor, in patients with septic shock [34].